Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma (Q24186668)

6

0 references

Bastian von Tresckow

2

Bastian von Tresckow

0 references

Marie-Therese Sickinger

1

Marie-Therese Sickinger

0 references

Carsten Kobe

3

Carsten Kobe

0 references

Peter Borchmann

5

Cochrane Database of Systematic Reviews

Peter Borchmann

0 references

publication date

9 January 2015

0 references

published in

0 references

cites work

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 t

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Clinical manifestations and natural history of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Hodgkin's lymphoma: the pathologist's viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Incidence patterns and outcomes for hodgkin lymphoma patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

FDG-PET scan and treatment planning for early stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Epidemiology and etiology of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and predni

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010533.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD010533.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25572491

1 reference

Consolidated OpenCitations Corpus – April 2017